Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MESSINA: Benralizumab for Eosinophilic Esophagitis
jRCT2061200026Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing Benralizumab arm with Placebo arm (2 arms). Primary endpoints: Histologic response at Week 24 and Change in Dysphagia Symptom Questionnaire (DSQ) score at Week 24. Started Dec 2020; status: completed.
02
Drugs
benralizumab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on jRCT2061200026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061200026.